Ajust text size (less) Ajust text size (more)
Adjust text size

National webinars and special events

Back to previous page

PSA is excited to offer a national webinar series available to all members across Australia.

The one hour monthly webinar will enable you to interactively engage and question the expert speakers in real time from anywhere in Australia.

Multiple choice questions will be available online to enable you to gain Group 2 Credits for each webinar.

Webinars will be recorded and accessible to view a few days after the live webinar via the PSA Online Learning listing.

Practical considerations associated with biosimilar medicines – webinar @ Online
Jul 4 @ 7:30 pm – 9:00 pm

The introduction of biosimilar medicines has widened the scope of brand substitution in Australia. With nine brands of biosimilar medicines currently approved for use in Australia, seven of which are also listed on the PBS, pharmacists will be increasingly faced with opportunities to engage consumers in discussions about biosimilar substitution.

Biosimilar medicines encourage competition in the Australian market, leading to a reduction in the cost of medicines. Lower prices improve affordability of, and access to new treatments for seriously ill patients, and create savings for the healthcare system. It is essential that pharmacists are able to educated consumers about biosimilar medicines to facilitate safe and appropriate substitution.

Join Professor Geoff McColl, Associate Professor Michael Ward and Dr Esther Lau for an interactive Q&A session exploring practical considerations associated with biosimilar substitution, including the application of the revised Professional Practice Standards.


ACT, NSW, QLD, TAS & VIC – 7.30pm
SA & NT – 7pm
WA – 5.30pm

register now button

Note: PSA member number is required to register for the webinar.

Learning obectives

Upon completion of this activity, pharmacist should be able to:

  • Explain differences between generic medicines and biosimilar medicines.
  • Discuss practical considerations when substituting biological medicines.
  • Counsel patients on biosimilar medicines to facilitate safe and appropriate substitution.

This event addresses the following competency standards (2010): 1.1.3, 3.1.2, 3.2.3, 3.2.5.

This information is correct at the time of publication and subject to change.

CPD credits


This lecture is currently undergoing accreditation.


Professor Geoff McColl
Professor McColl is a visiting rheumatologist at the Royal Melbourne Hospital and past president of the Australian Rheumatology Association. He is currently a member of the Therapeutic Goods Administration Advisory Committee on Medicines and a past member of Pharmaceutical Benefits Advisory Committee and Chair of the Drug Utilisation Subcommittee. Professor McColl is also Head of the Melbourne Medical School and Professor of Medical Education and Training.

Associate Professor Michael Ward
Associate Professor Ward is Discipline Leader: Pharmacy Education at the School of Pharmacy and Medical Sciences, University of South Australia. He is currently a member of the Therapeutic Goods Administration Advisory Committee on the Safety of Medicines, and a member of South Australian Medicine Evaluation Panel. In 2016, Associate Professor Ward was commissioned to produce a Literature Review of International Biosimilar Medicines, by the Australian Government Department of Health.


This item is listed in the following categories: • Branch events


our vision: Improving health through excellence in the practice of pharmacy

' • '